

Special Issue

Recent Developments in Antimicrobial Resistance Epidemiology and Antimicrobial Therapy for Clinically Relevant Bacteria

Message from the Guest Editor

Antimicrobial resistance has emerged as one of the principal public health problems of our century, threatening the effective use of indispensable drugs for the treatment of infections. For decades, the development of new antibiotics has been facing a severe shortage. Nowadays, the treatment of multi-, extensively, and even pan-drug-resistant infections is based on limited last-resort options. Moreover, the optimal treatment choice often depends on other factors, including the underlying resistance mechanisms of the infected agent. Therefore, continuously updating the epidemiology of resistance mechanisms and antibiotic-resistant bacteria, combined with knowledge on recent developments in antimicrobials, is essential for healthcare professionals. This Special Issue seeks manuscript submissions that further our understanding of antimicrobial resistance in clinically relevant bacteria, improvements in the detection of these mechanisms in laboratory practice, and treatment solutions and observations. Submissions on the development of new antibiotic compounds or the in vitro susceptibility of relevant bacteria to these compounds are especially encouraged.

Guest Editor

Dr. Georgios Meletis

Department of Microbiology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

Deadline for manuscript submissions

30 June 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/251504

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)